Philips Healthcare of Andover, MA, and biopharmaceutical firm RXi Pharmaceuticals of Worcester, MA, have entered into a joint research agreement to explore combining proprietary technologies for the targeted delivery of experimental therapeutics based on RNA interference (RNAi).
Compounds based on RNAi represent a new class of drugs for the targeted treatment of a number of diseases, including cancer and cardiovascular disease.
The companies note that one challenge is finding ways to deliver RNAi-based therapeutics to targets while keeping them active. The joint research program will address the challenge by exploring, in preclinical studies, the possibility of using RXi's sd-rxRNA (self-delivering rxRNA) in conjunction with Philips' ultrasound technology to achieve the targeted delivery and monitoring of RNAi-based compounds in cells.
Related Reading
Philips teams with Electron in Russia, May 19, 2010
Philips inks deal with Orion, April 29, 2010
Philips grows Q1 sales by 7%, April 19, 2010
Philips nets iSite renewal deal, April 13, 2010
Sectra, Philips partner in Japan, April 9, 2010
Copyright © 2010 AuntMinnie.com
